Ipamorelin: Benefits, Mechanism, and What the Research Shows (2026)
Most claims about ipamorelin benefits describe outcomes that were measured in rats, not in people. Ipamorelin is a synthetic pentapeptide that tells the pituitary to release growth hormone, and it earned attention for doing that cleanly, without the cortisol and prolactin spikes seen with older compounds. What it has not done is clear a human efficacy trial.
The Compound Universe Take: Ipamorelin is a selective growth hormone secretagogue (a ghrelin-receptor agonist) first described in 1998. Its documented benefits are preclinical: in animal studies it raised growth hormone pulses and increased longitudinal bone growth without lifting cortisol, prolactin, or ACTH. In humans, the one published efficacy trial (for postoperative ileus) failed its primary endpoint, and the compound is not FDA-approved. Treat it as a research peptide, not a proven therapy.
New to this class? Start with the growth hormone peptides overview for the wider class, then use this page for the compound-specific evidence.
What ipamorelin is
Ipamorelin is a five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) originally developed by Novo Nordisk and first reported by Raun and colleagues in 1998 [1]. It belongs to the growth-hormone-releasing peptide (GHRP) family and works at the ghrelin receptor, formally the growth hormone secretagogue receptor (GHSR-1a).
The reason it stood out was selectivity. Earlier secretagogues released growth hormone but also nudged stress and reproductive hormones. Ipamorelin released growth hormone at a potency comparable to GHRP-6 while leaving cortisol, prolactin, ACTH, and thyroid hormones essentially flat, even at doses far above the level needed for the growth-hormone effect [1].
The quick-facts table below summarizes the compound before the mechanism and evidence sections go deeper.
| Attribute | Detail |
|---|---|
| Class | Pentapeptide; selective growth hormone secretagogue (ghrelin / GHSR-1a agonist) |
| Most studied for | Growth hormone release, bone growth, body weight gain (animal models) |
| Evidence tier | Mostly Animal; one failed Human pilot (postoperative ileus) |
| Legal status (US) | Not FDA-approved; sold for research use only; WADA-prohibited in sport |
How ipamorelin works: the ghrelin receptor and growth hormone release
Ipamorelin binds the GHSR-1a receptor on somatotroph cells in the anterior pituitary, the same receptor the hunger hormone ghrelin uses. Activating that receptor triggers intracellular calcium release, which prompts the pituitary to secrete stored growth hormone in a pulse. (Mechanism, animal and in-vitro.)
This is an indirect, upstream route. Ipamorelin does not add growth hormone to the body; it signals the gland to release its own. In conscious swine the peptide released growth hormone with an ED50 of about 2.3 nmol/kg, closely matching GHRP-6 in potency [1]. (Animal.)
Because the growth-hormone pulse eventually raises insulin-like growth factor 1 (IGF-1) in most secretagogue models, ipamorelin is often grouped with growth-hormone-axis peptides. Notably, the 15-day rat bone study did not detect a rise in total IGF-1, so the downstream signaling is not fully characterized [2]. (Animal.)
What the research supports (and what it does not)
Growth hormone and bone: the animal evidence
The clearest documented benefit comes from a 1999 rat study by Johansen and colleagues [2]. Ipamorelin given three times daily for 15 days increased longitudinal bone growth in a dose-dependent way, from 42 micrometers per day in controls up to 52 micrometers per day at the highest dose, alongside dose-dependent body-weight gain and larger growth-hormone pulses. (Animal.)
That study also flagged a limit worth keeping: the treatment did not change total IGF-1, IGF-binding proteins, or standard serum markers of bone formation and resorption [2]. The bone effect was real in the model, but its mechanism was not fully explained. (Animal.)
Selectivity: the hormone-specificity finding
The signature ipamorelin benefit reported in the literature is what it does not do. The original characterization showed growth-hormone release without meaningful elevation of ACTH, cortisol, FSH, LH, prolactin, or TSH, even at doses 200-fold above the growth-hormone ED50 [1]. That selectivity is why Raun titled the paper “the first selective growth hormone secretagogue.” (Animal and in-vitro.)
The human record: one trial, no efficacy
Human data are thin. Beyond early pharmacokinetic work [3], the main clinical test was a Phase 2 randomized trial of ipamorelin for postoperative ileus (slowed gut recovery after surgery), run under NCT00672074 [4]. The program was discontinued after the compound did not meet its efficacy goal in that setting. (Human pilot.)
No published randomized trial supports ipamorelin for anti-aging, fat loss, muscle gain, or general “growth hormone optimization” in healthy adults. Those popular claims rest on the animal growth-hormone data plus extrapolation, not on human outcomes. (No human efficacy evidence.)
Read this before the marketing: Ipamorelin is not FDA-approved and is sold “for research use only.” This page summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. It is also banned in competitive sport under the World Anti-Doping Agency. Legal status varies by jurisdiction and is changing.
| Dimension | Mechanism / finding | Evidence maturity | Regulatory status (US) |
|---|---|---|---|
| GH release | Ghrelin-receptor (GHSR-1a) agonism triggers pituitary GH pulse | Animal + in-vitro | Not FDA-approved |
| Bone / weight | Dose-dependent longitudinal bone growth and body-weight gain in rats | Animal (15-day study) | Not FDA-approved |
| Selectivity | GH release without ACTH, cortisol, or prolactin rise | Animal + in-vitro | Not FDA-approved |
| Human use | Postoperative ileus trial failed its primary endpoint | Human pilot (discontinued) | Investigational; program halted |
Key takeaways
- Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor (GHSR-1a) to prompt a pituitary growth-hormone pulse [1].
- Its best-documented benefit is hormone selectivity: growth-hormone release without raising cortisol, prolactin, or ACTH in animal models [1].
- In rats, ipamorelin increased longitudinal bone growth and body weight dose-dependently, yet did not raise total IGF-1 [2].
- The single published human efficacy trial, for postoperative ileus, failed and the program was discontinued [4].
- Ipamorelin is not FDA-approved, is sold for research use only, and is prohibited in competitive sport by WADA.
Frequently asked questions
What are the main benefits of ipamorelin in research?
In animal studies, ipamorelin raised growth-hormone pulses, increased longitudinal bone growth, and did so without elevating cortisol or prolactin [1][2]. These are preclinical findings, not confirmed human outcomes.
Is ipamorelin FDA-approved?
No. Ipamorelin has no approved pharmaceutical status and is marketed as a research peptide. Its one published human efficacy trial did not meet its endpoint [4].
How is ipamorelin different from CJC-1295?
Ipamorelin is a ghrelin-receptor secretagogue that triggers a growth-hormone pulse, while CJC-1295 is a long-acting GHRH analog that sustains growth-hormone and IGF-1 output over days [5]. They act on different receptors and are often studied as complementary mechanisms.
Does ipamorelin raise cortisol or prolactin?
In the original characterization it did not, even at doses well above the growth-hormone threshold [1]. That selectivity is the trait most often cited to distinguish it from older growth-hormone-releasing peptides.
Is ipamorelin proven to build muscle or reduce fat?
No published human trial demonstrates muscle gain or fat loss from ipamorelin. Those claims extrapolate from animal growth-hormone data rather than controlled human results.
Is ipamorelin legal?
It is not FDA-approved and is sold for research use only in the United States, and it is banned in competitive sport under WADA rules. Legal status differs by jurisdiction and changes, so verify current status before relying on any claim.
Ipamorelin sits within the growth-hormone secretagogue family alongside GHRP-6, hexarelin, and the GHRH analog CJC-1295, acting through the ghrelin receptor (GHSR-1a) on anterior pituitary somatotrophs to release endogenous growth hormone in a pulse that can, in most models, feed the downstream IGF-1 axis; Compound Universe tracks this pentapeptide against its primary literature (Raun’s selectivity work, Johansen’s rat bone study, and the discontinued postoperative-ileus trial) so its evidence tier reflects what was actually measured rather than what is marketed.
Read carefully, the honest version of ipamorelin benefits is narrow: a selective growth-hormone pulse with a clean hormone profile in animals, a dose-dependent bone effect in rats, and no completed human efficacy trial. It is a well-characterized research peptide, not an approved treatment, and the gap between its animal data and the human claims made for it is the single most important thing to understand before reading any marketing.
Compare next: ipamorelin vs CJC-1295 | CJC-1295 research summary | see the full GH peptide class
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822.
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID 10373343.
- Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID 10496658.
- Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus. ClinicalTrials.gov identifier NCT00672074 (Phase 2; program discontinued for lack of efficacy).
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683.